| # | Title | Journal | Year | Citations |
|---|
| 1 | The antibiotic resistance crisis: part 1: causes and threats | P and T | 2015 | 1,728 |
| 2 | Medical Applications for 3D Printing: Current and Projected Uses | P and T | 2014 | 392 |
| 3 | Progress in Nanomedicine: Approved and Investigational Nanodrugs | P and T | 2017 | 347 |
| 4 | Mobile devices and apps for health care professionals: uses and benefits | P and T | 2014 | 334 |
| 5 | Social media and health care professionals: benefits, risks, and best practices | P and T | 2014 | 306 |
| 6 | Multiple sclerosis review | P and T | 2012 | 284 |
| 7 | Interpreting estimates of treatment effects: implications for managed care | P and T | 2008 | 221 |
| 8 | Schizophrenia: overview and treatment options | P and T | 2014 | 165 |
| 9 | Osteoporosis: A Review of Treatment Options | P and T | 2018 | 161 |
| 10 | Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis | P and T | 2015 | 153 |
| 11 | The antibiotic resistance crisis: part 2: management strategies and new agents | P and T | 2015 | 146 |
| 12 | Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting | P and T | 2017 | 123 |
| 13 | How patient cost-sharing trends affect adherence and outcomes: a literature review | P and T | 2012 | 122 |
| 14 | Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment | P and T | 2010 | 116 |
| 15 | Personalized medicine: part 1: evolution and development into theranostics | P and T | 2010 | 114 |
| 16 | Cancer Immunotherapy, Part 3: Challenges and Future Trends | P and T | 2017 | 109 |
| 17 | Drugs for Alzheimer's disease: are they effective? | P and T | 2010 | 104 |
| 18 | The burden of psoriatic arthritis: a literature review from a global health systems perspective | P and T | 2010 | 92 |
| 19 | Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma | P and T | 2010 | 85 |
| 20 | The drug shortage crisis in the United States: causes, impact, and management strategies | P and T | 2011 | 84 |
| 21 | Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer | P and T | 2011 | 77 |
| 22 | Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use | P and T | 2012 | 76 |
| 23 | Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths | P and T | 2009 | 74 |
| 24 | Overview of omega-3 Fatty Acid therapies | P and T | 2013 | 72 |
| 25 | Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 1: The Widespread Use of CAM and the Need for Better-Informed Health Care Professionals to Provide Patient Counseling | P and T | 2010 | 69 |
| 26 | Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? | P and T | 2011 | 69 |
| 27 | The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma | P and T | 2013 | 69 |
| 28 | The nanomedicine revolution: part 1: emerging concepts | P and T | 2012 | 68 |
| 29 | Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction | P and T | 2013 | 58 |
| 30 | Lupus: an overview of the disease and management options | P and T | 2012 | 56 |
| 31 | Current diagnosis and treatment of anxiety disorders | P and T | 2013 | 55 |
| 32 | Pharmacological therapies for autism spectrum disorder: a review | P and T | 2015 | 55 |
| 33 | Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange | P and T | 2010 | 54 |
| 34 | Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia | P and T | 2009 | 51 |
| 35 | Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations | P and T | 2016 | 51 |
| 36 | Cancer Immunotherapy, Part 1: Current Strategies and Agents | P and T | 2017 | 50 |
| 37 | The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge | P and T | 2016 | 49 |
| 38 | Rosacea: a review | P and T | 2009 | 48 |
| 39 | Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis | P and T | 2018 | 45 |
| 40 | A review of abuse-deterrent opioids for chronic nonmalignant pain | P and T | 2012 | 44 |
| 41 | EHRs: The Challenge of Making Electronic Data Usable and Interoperable | P and T | 2017 | 44 |
| 42 | Guidelines for standard order sets | P and T | 2014 | 43 |
| 43 | Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia | P and T | 2014 | 43 |
| 44 | Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview | P and T | 2015 | 43 |
| 45 | The nanomedicine revolution: part 2: current and future clinical applications | P and T | 2012 | 41 |
| 46 | Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches | P and T | 2013 | 41 |
| 47 | Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection | P and T | 2015 | 40 |
| 48 | Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions | P and T | 2011 | 39 |
| 49 | Potassium-Binding Agents for the Clinical Management of Hyperkalemia | P and T | 2016 | 39 |
| 50 | Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes | P and T | 2010 | 38 |
